Evidence map›Paper›PMID 38470175›Full record

ArticleEpilepsia2024

Comprehensive phenotypes of patients with SYNGAP1-related disorder reveals high rates of epilepsy and autism.

Kimberly Wiltrout, Elise Brimble, Annapurna Poduri

Open access · bronzeAbstract read
In one paragraph

Article in Epilepsia, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 2 pooled it
11.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 2 syntheses or guidelines pooled it, 21 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Review
  6. Epilepsy associated withFrontiers in pediatrics · 2026
    Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Clinical signatures of SYNGAP1-related disorders through data integration.Genetics in medicine : official journal of the American College of Medical Genetics · 2025
    Article
  12. Review
  13. Article
  14. Unveiling a de novoSAGE open medical case reports · 2024
    Article
  15. Research progress inFrontiers in neurology
    Review
  16. Roadmap to advance therapeutics forTherapeutic advances in rare disease
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Kimberly WiltroutDepartment of Neurology, Boston Children's Hospital and Harvard Medical School, Boston, Massachusetts, USA.ORCID https://orcid.org/0000-0001-8123-4092
Elise BrimbleInvitae Corporation, San Francisco, California, USA.ORCID https://orcid.org/0000-0002-7238-7342
Annapurna PoduriDepartment of Neurology, Boston Children's Hospital and Harvard Medical School, Boston, Massachusetts, USA.ORCID https://orcid.org/0000-0002-7350-5136
Boston Children's Hospital · USInvitae (United States) · US

Funding

Genetic Analysis and Manipulation Core (GAEC)P50HD105351 · NICHD · BOSTON CHILDREN'S HOSPITAL · PI SCOTT Loren POMEROY, MUSTAFA SAHIN · 2021 to 2026
$9.4M
SYNGAP1: Charting our Rare Disease Treatment PathR13NS130932 · NINDS · BOSTON CHILDREN'S HOSPITAL · PI PODURI, ANNAPURNA, WILTROUT, KIMBERLY · 2022 to 2022
$25k
NICHD NIH HHS P50 HD105351NINDS NIH HHS R13 NS130932SYNGAP Research Fund
6 · The paper itself

Abstract

objectiveTo delineate the comprehensive phenotypic spectrum of SYNGAP1-related disorder in a large patient cohort aggregated through a digital registry.

methodsWe obtained de-identified patient data from an online registry. Data were extracted from uploaded medical records. We reclassified all SYNGAP1 variants using American College of Medical Genetics criteria and included patients with pathogenic/likely pathogenic (P/LP) single nucleotide variants or microdeletions incorporating SYNGAP1. We analyzed neurodevelopmental phenotypes, including epilepsy, intellectual disability (ID), autism spectrum disorder (ASD), behavioral disorders, and gait dysfunction for all patients with respect to variant type and location within the SynGAP1 protein.

resultsWe identified 147 patients (50% male, median age 8 years) with P/LP SYNGAP1 variants from 151 individuals with data available through the database. One hundred nine were truncating variants and 22 were missense. All patients were diagnosed with global developmental delay (GDD) and/or ID, and 123 patients (84%) were diagnosed with epilepsy. Of those with epilepsy, 73% of patients had GDD diagnosed before epilepsy was diagnosed. Other prominent features included autistic traits (n = 100, 68%), behavioral problems (n = 100, 68%), sleep problems (n = 90, 61%), anxiety (n = 35, 24%), ataxia or abnormal gait (n = 69, 47%), sensory problems (n = 32, 22%), and feeding difficulties (n = 69, 47%). Behavioral problems were more likely in those patients diagnosed with anxiety (odds ratio [OR] 3.6, p = .014) and sleep problems (OR 2.41, p = .015) but not necessarily those with autistic traits. Patients with variants in exons 1-4 were more likely to have the ability to speak in phrases vs those with variants in exons 5-19, and epilepsy occurred less frequently in patients with variants in the SH3 binding motif. SIGNIFICANCE: We demonstrate that the data obtained from a digital registry recapitulate earlier but smaller studies of SYNGAP1-related disorder and add additional genotype-phenotype relationships, validating the use of the digital registry. Access to data through digital registries broadens the possibilities for efficient data collection in rare diseases.

Indexed as

Autism Spectrum DisorderEpilepsyPhenotyperas GTPase-Activating ProteinsAdolescentAdultAutistic DisorderChildChild, PreschoolCohort StudiesDevelopmental DisabilitiesFemaleHumansInfantIntellectual DisabilityMaleras GTPase-Activating ProteinsSYNGAP1 protein, humandevelopmental and epileptic encephalopathyepilepsy with eyelid myocloniaepilepsy with myoclonic–atonic seizuresgenetic generalized epilepsyintellectual disabilitySYNGAP1

Identifiers

PMID38470175
PMCPMC12375243
OpenAlexW4392727902

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.